Aytu BioPharma (NASDAQ:AYTU) Rating Lowered to “Strong Sell” at Zacks Research

Aytu BioPharma (NASDAQ:AYTU) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Monday, Zacks reports.

Other equities analysts have also recently issued research reports about the stock. Ascendiant Capital Markets upped their price target on shares of Aytu BioPharma from $14.00 to $14.50 and gave the stock a “buy” rating in a research note on Thursday, June 11th. Citigroup reaffirmed a “positive” rating on shares of Aytu BioPharma in a report on Tuesday, September 22nd. Finally, Weiss Ratings upgraded shares of Aytu BioPharma from a “sell (d-)” rating to a “sell (d)” rating in a research note on Tuesday, September 22nd. Two equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $14.50.

Aytu BioPharma Price Performance

Shares of NASDAQ:AYTU opened at $2.05 on Monday. Aytu BioPharma has a 1-year low of $1.80 and a 1-year high of $3.07. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.13 and a quick ratio of 1.00. The business has a fifty day moving average price of $2.22 and a 200-day moving average price of $2.30. The company has a market capitalization of $22.28 million, a PE ratio of -1.23 and a beta of 0.17.

Institutional Investors Weigh In On Aytu BioPharma

Institutional investors have recently modified their holdings of the business. Nantahala Capital Management LLC bought a new stake in Aytu BioPharma in the 2nd quarter worth about $2,336,646. Stonepine Capital Management LLC bought a new position in Aytu BioPharma during the 2nd quarter valued at about $1,962,780. AWM Investment Company Inc. purchased a new stake in shares of Aytu BioPharma during the 2nd quarter valued at about $1,332,000. BlackRock Inc. purchased a new stake in shares of Aytu BioPharma during the 2nd quarter valued at about $49,000. Finally, Crown Advisors Management Inc. bought a new stake in shares of Aytu BioPharma in the second quarter worth approximately $430,000. 33.49% of the stock is owned by hedge funds and other institutional investors.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on commercializing prescription medicines, primarily for pediatric and primary-care markets. The company’s activities include acquiring, developing and commercializing products intended to address unmet needs in areas such as attention deficit hyperactivity disorder (ADHD), allergies and other common medical conditions.

Aytu’s ADHD portfolio has included Adzenys XR-ODT, an orally disintegrating extended-release amphetamine tablet; Cotempla XR-ODT, an orally disintegrating extended-release methylphenidate tablet; and Dyanavel XR, an extended-release liquid amphetamine formulation.